

ANNOUNCEMENT OF ALLOTMENT RESULTS

SUMMARY

Net Proceeds from the Global Offering

- Based on the Offer Price of HK\$7.89 per Offer Share, the net proceeds from the Global Offering to be received by the Company, after deduction of underwriting fees and commissions and estimated expenses payable by the Company in connection with the Global Offering and assuming the Over-allotment Option is not exercised, is estimated to be approximately HK\$760.9 million. The Company intends to apply such net proceeds in accordance with the purposes set out in the section headed “Future Plans and Use of Proceeds” in the Prospectus.
- If the Over-allotment Option is exercised in full, the Company will receive additional net proceeds of approximately HK\$156.0 million for 20,728,000 additional Offer Shares to be issued and allotted upon the exercise of the Over-allotment Option. In the event that the Over-allotment Option is exercised, the Company will apply the net proceeds to the purposes and in the proportions as set out in the paragraph headed “Net Proceeds from the Global Offering” in this announcement.

Applications and Indications of Interest Received in the Hong Kong Public Offering

- The Hong Kong Offer Shares initially offered under the Hong Kong Public Offering have been slightly over-subscribed. A total of 4,025 valid applications have been received pursuant to the Hong Kong Public Offering through the **HK eIPO White Form** service and through the **CCASS EIPO** service for a total of 18,694,000 Hong Kong Offer Shares, representing approximately 1.35 times of the total number of 13,819,000 Hong Kong Offer Shares initially available for subscription under the Hong Kong Public Offering.
- As the over-subscription in the Hong Kong Public Offering is less than 15 times of the number of Offer Shares initially available under the Hong Kong Public Offering, no reallocation procedure as described in the section headed “Structure of the Global Offering – The Hong Kong Public Offering – Reallocation” in the Prospectus has been applied. The final number of Offer Shares under the Hong Kong Public Offering is 13,819,000, representing approximately 10% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option) and being allocated to 4,025 successful applicants under the Hong Kong Public Offering, among which 2,532 shareholders were allotted one board lot of Shares.

International Offering

- The Offer Shares initially offered under the International Offering have been slightly over-subscribed, representing approximately 1.39 times of the total number of Offer Shares initially available under the International Offering. There is no reallocation of Offer Shares between the Hong Kong Public Offering and the International Offering, and the final number of Offer Shares under the International Offering is 124,369,000 Shares, representing approximately 90% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option). There has been an over-allocation of 20,728,000 Offer Shares and there are a total of 136 places under the International Offering.
- A total of 100 places have been allotted five board lots of Offer Shares or less, representing approximately 73.52% of 136 places under the International Offering. These places have been allotted 61,500 Shares in total, representing approximately 0.05% of the Offer Shares initially available under the International Offering (assuming the Over-allotment Option is not exercised). A total of 82 places have been allotted one board lot of Offer Shares, representing approximately 60.29% of 136 places under the International Offering. These places have been allotted 41,000 Shares in total, representing approximately 0.03% of the Offer Shares initially available under the International Offering (assuming the Over-allotment Option is not exercised).

Cornerstone Investors

- Based on the Offer Price of HK\$7.89 per Offer Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015%) and pursuant to the Cornerstone Investment Agreements, the Cornerstone Investors have subscribed for a total of 37,791,500 Offer Shares, representing in aggregate (a) approximately 6.17% of the total issued share capital of the Company immediately upon completion of the Global Offering and (b) approximately 27.35% of the number of Offer Shares under the Global Offering, in each case assuming the Over-allotment Option is not exercised. Please refer to the section headed “Cornerstone Placing” in the Prospectus for further details of the Cornerstone Investors.

Places with the Consent under Paragraph 5(1) of Placing Guidelines

- The Company has applied to the Stock Exchange for, and the Stock Exchange has granted to the Company, its consent under paragraph 5(1) of Appendix 6 to the Listing Rules (the “**Placing Guidelines**”) to permit the Company to allocate Offer Shares in the International Offering to the places set out in the section headed “International Offering – Places with the Consent under Paragraph 5(1) of the Placing Guidelines” in this announcement.

- None of the Joint Sponsors, the Joint Representatives, the Joint Global Coordinators, the Joint Bookrunners, the Joint Lead Managers, the Underwriters and their respective affiliated companies and connected clients of the lead broker or of any distributors (as defined in the Placing Guidelines) has taken up any Offer Shares for its own benefit under the Global Offering. The Offer Shares placed to the places set out in the section headed “International Offering – Places with the Consent under Paragraph 5(1) of the Placing Guidelines” in this announcement are in compliance with all the conditions under the consent granted by the Stock Exchange. There is no restriction on disposal of the Offer Shares allocated to each of such connected clients.

Over-allotment Option

- In connection with the Global Offering, the Company has granted the Over-allotment Option to the International Underwriters, exercisable by the Joint Representatives on behalf of the International Underwriters, at any time from the Listing Date to Friday, June 10, 2022, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering, to require the Company to allot and issue up to an aggregate of 20,728,000 additional Offer Shares, representing approximately 15% of the initial number of Offer Shares to be offered in the Global Offering, at the Offer Price to cover over-allocations in the International Offering, if any. There has been an over-allocation of 20,728,000 Offer Shares in the International Offering and such over-allocation will be settled by using Shares to be borrowed under the Stock Borrowing Agreement between YK Development and the Stabilizing Manager. Such borrowed Shares will be covered by exercising the Over-allotment Option in full or in part, or by making purchases in the secondary market at prices that do not exceed the Offer Price, or a combination of these means. In the event the Over-allotment Option is exercised, an announcement will be made on the Company’s website at www.yunkanghealth.com and on the Stock Exchange’s website at www.hkexnews.hk, respectively. As of the date of this announcement, the Over-allotment Option has not been exercised.

Lock-up Undertakings

- Each of the Company, Controlling Shareholders, Warranting Shareholders and Cornerstone Investors has entered into Lock-up Undertakings and/or are subject to certain Lock-up Undertakings as set out in the paragraph headed “Lock-up Undertakings” in this announcement.

Results of Allocations

- The level of indications of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares will be published on Tuesday, May 17, 2022 on the website of the Stock Exchange at www.hkexnews.hk and the Company’s website at www.yunkanghealth.com.

- The results of allocations of the Hong Kong Offer Shares under the Hong Kong Public Offering successfully applied for through the **HK eIPO White Form** service or through the **CCASS EIPO** service, including the Hong Kong identity card, passport, Hong Kong business registration and certificate of incorporation numbers of successful applicants (where applicable) and the number of Hong Kong Offer Shares successfully applied for, will be made available at the times and dates and in the manner specified below:
 - in the announcement to be posted on the Company’s website and the Stock Exchange’s website at www.yunkanghealth.com and www.hkexnews.hk, respectively, by no later than 8:00 a.m. on Tuesday, May 17, 2022. Please note that the list of identification document numbers in this announcement may not be a complete list of successful applicants since only successful applicants whose identification document numbers are provided to HKSCC by CCASS Participants are disclosed. Applicants with beneficial names only but not identification document numbers are not disclosed due to personal privacy issue as elaborated below. Applicants who applied for the Offer Shares through their brokers can consult their brokers to enquire about their application result;
 - from the “IPO Results” function in the **IPO App** or the designated results of allocations website at www.tricor.com.hk/ipo/result or www.hkeipo.hk/IPOResult with a “search by ID” function on a 24-hour basis from 8:00 a.m. on Tuesday, May 17, 2022 to 12:00 midnight on Monday, May 23, 2022; and
 - from the results allocation telephone enquiry line by calling +852 3691 8488 between 9:00 a.m. and 6:00 p.m. on Tuesday, May 17, 2022 to Friday, May 20, 2022.
- This announcement contains a list of identification document numbers. Identification document numbers shown in the section headed “Results of Applications Made by **HK eIPO White Form**” refer to Hong Kong identity card numbers/passport numbers/Hong Kong business registration numbers/certificate of incorporation numbers/beneficial owner identification codes (if such applications are made by nominees as agent for the benefit of another person) whereas those displayed in the section headed “Results of Applications Made by Giving **Electronic Application Instructions** to HKSCC via CCASS” are provided by CCASS Participants via CCASS. Therefore, the identification document numbers shown in the two sections are different in nature.
- Since applications are subject to personal information collection statements, beneficial owner identification codes displayed in the sections headed “Results of Applications Made by **HK eIPO White Form**” and “Results of Applications Made by Giving **Electronic Application Instructions** to HKSCC via CCASS” are redacted and not all details of applications are disclosed in this announcement.

Despatch/Collection of Share Certificates and Refund Monies

- Applicants who applied for 1,000,000 Hong Kong Offer Shares or more through the **HK eIPO White Form** service and who have been successfully or partially successfully allocated Hong Kong Offer Shares and are eligible to collect Share certificates in person may collect Share certificates from the Hong Kong Share Registrar, Tricor Investor Services Limited, at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong, from 9:00 a.m. to 1:00 p.m. on Tuesday, May 17, 2022, or such other date as notified by the Company in the newspapers as the date of despatch/collection of Share certificates/refund monies.
- Applicants being individuals who are eligible for personal collection cannot authorize any other person to make collection on their behalf. Corporate applicants which are eligible for personal collection must attend by their authorised representatives bearing letters of authorisation from their corporations stamped with the corporations' chops. Both individuals and authorised representatives (if applicable) must produce, at the time of collection, evidence of identity acceptable to Tricor Investor Services Limited.
- Share certificates for Hong Kong Offer Shares allotted to applicants who applied for less than 1,000,000 Hong Kong Offer Shares through the **HK eIPO White Form** service are expected to be despatched to those entitled to the addresses specified in the relevant application instructions by ordinary post at their own risk on or before Tuesday, May 17, 2022.
- Share certificates for Hong Kong Offer Shares allocated to applicants who applied through the **HK eIPO White Form** service which are either not available for personal collection or which are available but are not collected in person by 1:00 p.m. on Tuesday, May 17, 2022, are expected to be despatched by ordinary post to those entitled to the address specified in the relevant application at their own risk on or before Tuesday, May 17, 2022.
- Wholly or partially successful applicants who applied by giving **electronic application instructions** to HKSCC via CCASS will have their Share certificates issued in the name of HKSCC Nominees Limited and deposited into CCASS for credit to their CCASS Investor Participant stock accounts or the stock accounts of their designated CCASS Participants who gave **electronic application instructions** on their behalf on Tuesday, May 17, 2022.
- Applicants who applied through a designated CCASS Participant (other than a CCASS Investor Participant) should check the number of Hong Kong Offer Shares allocated to them with that CCASS Participant.
- Applicants who applied through the **HK eIPO White Form** service and paid the application monies from a single bank account will have refund monies (if any) despatched to their application payment accounts in the form of e-Auto Refund payment instructions on Tuesday, May 17, 2022. Applicants who applied through the **HK eIPO White Form** service and paid the application monies from multiple bank accounts will have refund monies (if any) despatched to the addresses specified in their application instructions in the form of refund cheque(s) in favour of the applicant (or, in the case of joint applications, the first-named applicant) by ordinary post at their own risk on or before Tuesday, May 17, 2022. No interest will be paid thereon.

- Refund monies for applicants who have applied by giving electronic application instructions to HKSCC via CCASS are expected to be credited to the relevant applicants' designated bank accounts or the designated bank accounts of their brokers or custodians on Tuesday, May 17, 2022.
- Share certificates will only become valid certificates of title at 8:00 a.m. on the Listing Date which is expected to be Wednesday, May 18, 2022, provided that the Global Offering has become unconditional in all respects at or before that time and the right of termination described in the section headed "Underwriting – Underwriting Arrangements – Hong Kong Public Offering – Grounds for Termination" in the Prospectus has not been exercised.
- The Company will not issue any temporary documents of title in respect of the Offer Shares and will not issue any receipt for application monies received.

Compliance with Placing Guidelines

- Save as disclosed in the section headed "International Offering – Placees with the Consent under Paragraph 5(1) of the Placing Guidelines" in this announcement, the International Offering is in compliance with the Placing Guidelines. No Offer Shares placed by or through the Joint Global Coordinators and the Underwriters under the Global Offering have been placed with any core connected person (as defined in the Listing Rules) of the Company and save as disclosed in this announcement, to any connected clients (as set out in paragraph 5(1) of the Placing Guidelines), or persons as set out in paragraph 5(2) of the Placing Guidelines, whether in their own names or through nominees.
- The Directors confirm that, to the best of their knowledge, information and belief and having made all reasonable enquiries, no Offer Shares under the International Offering have been allocated to placees who are Directors, existing Shareholders of the Company or beneficial owners of Shares and/or any securities of the Company's subsidiaries or their respective close associates and core connected persons of the Company within the meaning of the Listing Rules, whether in their own names or through nominees, and that all placees and the public who have subscribed for the Offer Shares and their beneficial owners are independent of and not connected with the Company.

Public Float

- Immediately following the completion of the Global Offering, assuming the Over-allotment Option is not exercised, except for the Shares held by YK Development and Daan International, the Shares held by other Shareholders, representing 25.00% of the total issued share capital of the Company, will be counted towards the public float, which satisfies the minimum percentage prescribed in Rule 8.08(1) of the Listing Rules. The Directors confirm that immediately after the Global Offering, (i) no placee will, individually, be placed more than 10% of the enlarged issued share capital of the Company, (ii) there will not be any new substantial shareholder (as defined in the Listing Rules) of the Company, (iii) the number of Shares in public hands will satisfy the minimum percentage as prescribed under Rule 8.08(1) of the Listing Rules, (iv) the three largest public Shareholders do not hold more than 50% of the shares held in public hands at the time of the Listing in compliance with Rules 8.08(3) and 8.24 of the Listing Rules and, (v) there will be at least 300 Shareholders at the time of the Listing in compliance with Rule 8.08(2) of the Listing Rules.
- The Directors confirm that none of the Offer Shares subscribed by the placees or the public has been financed directly or indirectly by any of the Directors, chief executive, Controlling Shareholders, substantial Shareholders or existing Shareholders of the Company or any of its subsidiaries or their respective close associates, and none of the placees and the public who has subscribed for the Offer Shares is accustomed to taking instructions from any of the Directors, chief executive, Controlling Shareholders, substantial Shareholders or existing Shareholders of the Company or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of Shares registered in his/her/its name or otherwise held by him/her/it.

Commencement of Dealings

- Assuming the Global Offering becomes unconditional in all respects at or before 8:00 a.m. on Wednesday, May 18, 2022 (Hong Kong time), dealing in the Shares on the Stock Exchange are expected to commence at 9:00 a.m. on Wednesday, May 18, 2022 (Hong Kong time). Shares will be traded in board lots of 500 Shares each. The stock code of the Shares is 2325.

In view of the high concentration of shareholding in a small number of Shareholders, Shareholders and prospective investors should be aware that the price of the Shares could move substantially even with a small number of Shares traded and should exercise extreme caution when dealing in the Shares.

NET PROCEEDS FROM THE GLOBAL OFFERING

Based on the Offer Price of HK\$7.89 per Offer Share, the net proceeds from the Global Offering to be received by the Company after deduction of underwriting fees and expenses payable by the Company in connection with the Global Offering are estimated to be approximately HK\$760.9 million (assuming the Over-allotment Option is not exercised).

The Company intends to apply the net proceeds as follows:

- (i) Approximately 55.0%, or HK\$418.5 million, for expanding and deepening the Company's medical institution alliance network over the next four years, primarily in Eastern China (Shanghai, Anhui, Jiangsu and Zhejiang), Central China (Hubei, Sichuan, Chongqing, Yunnan and Guizhou) and Southern China (Guangdong, Guangxi, Fujian and Hunan).
 - (a) approximately 24.4%, or HK\$185.7 million will be used for establishing approximately 255 new pathology diagnostic centers;
 - (b) approximately 24.4%, or HK\$185.7 million will be used for establishing approximately 255 new infectious disease diagnostic centers; and
 - (c) approximately 6.2%, or HK\$47.2 million will be used for establishing approximately 19 new genetic disease diagnostic centers in China.
- (ii) Approximately 20.0%, or HK\$152.2 million, for upgrading and enhancing the Company's operational capabilities of a medical operation service provider to improve operational efficiency and digitalize testing services over the next three years.
 - (a) approximately 10.0%, or HK\$76.1 million will be used for developing four to five small-scale self-operated laboratories to serve regional customers in different provinces in China, including Guangdong, Hebei, Guizhou and Hunan;
 - (b) approximately 6.0%, or HK\$45.7 million will be used for the research, development and application of an intelligent imaging reading system for pathology tests; and
 - (c) approximately 4.0%, or HK\$30.4 million will be used for the research, development and application of an information technology system to better serve medical institution alliances in China.
- (iii) Approximately 10.0%, or HK\$76.1 million, for expanding the Company's diagnostic capabilities in key technologies over the next three years.
- (iv) Approximately 5.0%, or HK\$38.0 million, for potential investment and acquisition opportunities.
- (v) Approximately 5.0%, or HK\$38.0 million, for recruiting and training up the Company's talent pool, with a focus on management and technical personnel.
- (vi) Approximately 5.0%, or HK\$38.0 million, for the Company's working capital and general corporate purposes.

If the Over-allotment Option is exercised in full, the Company will receive additional net proceeds of approximately HK\$156.0 million for 20,728,000 additional Offer Shares to be issued and allotted upon the exercise of the Over-allotment Option. In the event that the Over-allotment Option is exercised, the Company will apply the additional net proceeds to the purposes and in the proportions as set out in the paragraph headed “Net Proceeds from the Global Offering” in this announcement.

To the extent that the net proceeds from the Global Offering are not immediately applied to the above purposes and to the extent permitted by the relevant law and regulations, so long as it is deemed to be in the best interest of the Company, the Company intends to allocate part or all of the proceeds to short-term interest-bearing deposits with licensed banks or authorized financial institutions in Hong Kong. In the event of any material change in the use of net proceeds of the Global Offering from the purposes described above or in the Company’s allocation of the net proceeds among the purposes described above, a formal announcement will be made.

For further information, please refer to the section headed “Future Plans and Use of Proceeds” in the Prospectus.

APPLICATIONS AND INDICATIONS OF INTEREST RECEIVED IN THE HONG KONG PUBLIC OFFERING

The Hong Kong Offer Shares initially available under the Hong Kong Public Offering have been slightly over-subscribed. At the close of the application lists at 12:00 noon on Wednesday, May 11, 2022, a total of 4,025 valid applications have been received pursuant to the Hong Kong Public Offering through the **HK eIPO White Form** service and through the **CCASS EIPO** service for a total of 18,694,000 Hong Kong Offer Shares, representing approximately 1.35 times of the total number of 13,819,000 Hong Kong Offer Shares initially available for subscription under the Hong Kong Public Offering, among which:

- 4,020 valid applications in respect of a total of 13,294,000 Hong Kong Offer Shares were for the Hong Kong Public Offering with an aggregate subscription amount based on the Offer Price of HK\$7.89 per Offer Share (excluding brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015%) of HK\$5 million or less, representing approximately 1.92 times of the 6,909,500 Hong Kong Offer Shares initially comprised in pool A; and
- Five valid applications in respect of a total of 5,400,000 Hong Kong Offer Shares were for the Hong Kong Public Offering with an aggregate subscription amount based on the Offer Price of HK\$7.89 per Offer Share (excluding brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015%) of more than HK\$5 million, representing approximately 0.78 times of the 6,909,500 Hong Kong Offer Shares initially comprised in pool B.

No application has been rejected due to invalid application. Two multiple or suspected multiple applications have been identified and rejected. No application has been rejected due to dishonoured payments. No application for more than 6,909,500 Hong Kong Offer Shares (being 50% of the Hong Kong Offer Shares initially available under the Hong Kong Public Offering) has been identified.

As the over-subscription in the Hong Kong Public Offering is less than 15 times of the number of Offer Shares initially available under the Hong Kong Public Offering, no reallocation procedure as described in the section headed “Structure of the Global Offering – The Hong Kong Public Offering – Reallocation” in the Prospectus has been applied. The final number of Offer Shares under the Hong Kong Public Offering is 13,819,000 Offer Shares, representing approximately 10% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option) and being allocated to 4,025 successful applicants under the Hong Kong Public Offering, among which 2,532 Shareholders were allotted one board lot of Shares.

The Offer Shares offered in the Hong Kong Public Offering were conditionally allocated on the basis set out in the paragraph headed “Basis of Allocation under the Hong Kong Public Offering” below.

INTERNATIONAL OFFERING

The Offer Shares initially offered under the International Offering have been slightly oversubscribed, representing approximately 1.39 times of the total number of Offer Shares initially available under the International Offering. There is no reallocation of Offer Shares between the Hong Kong Public Offering and the International Offering and the final number of Offer Shares under the International Offering is 124,369,000 Shares, representing approximately 90% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option). There has been an over-allocation of 20,728,000 Offer Shares and there are a total number of 136 places under the International Offering.

A total of 100 places have been allotted five board lots of Offer Shares or less, representing approximately 73.52% of 136 places under the International Offering. These places have been allotted 61,500 Shares in total, representing approximately 0.05% of the Offer Shares initially available under the International Offering (assuming the Over-allotment Option is not exercised). A total of 82 places have been allotted one board lot of Offer Shares, representing approximately 60.29% of 136 places under the International Offering. These places have been allotted 41,000 Shares in total, representing approximately 0.03% of the Offer Shares initially available under the International Offering (assuming the Over-allotment Option is not exercised).

Cornerstone Investors

Based on the Offer Price of HK\$7.89 per Offer Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015%) and pursuant to the Cornerstone Investment Agreements as disclosed in the section headed “Cornerstone Placing” in the Prospectus, the number of Offer Shares subscribed for by the Cornerstone Investors is determined as set out below:

		Based on an Offer Price of HK\$7.89				
		Assuming the Over-allotment Option is not exercised		Assuming the Over-allotment Option is fully exercised		
<i>Cornerstone Investor</i>	<i>Subscription Amount</i>	<i>Number of Offer Shares</i>	<i>Approximate % of the Offer Shares</i>	<i>Approximate % of the issued share capital</i>	<i>Approximate % of the Offer Shares</i>	<i>Approximate % of the issued share capital</i>
Harvest	US\$30,000,000	29,835,500	21.59%	4.87%	18.77%	4.71%
YHLO Hong Kong	US\$8,000,000	7,956,000	5.76%	1.30%	5.01%	1.26%
Total		<u>37,791,500</u>	<u>27.35%</u>	<u>6.17%</u>	<u>23.78%</u>	<u>5.97%</u>

The Company has confirmed that each of Cornerstone Investors (i) is an Independent Third Party and is not our connected person (as defined in the Listing Rules), (ii) is independent of other Cornerstone Investors, (iii) is not financed by us, our subsidiaries, our Directors, chief executive, existing Shareholders or their respective close associates, and (iv) is not accustomed to take instructions from us, our subsidiaries, our Directors, chief executive, existing Shareholders or their respective close associates in relation to the acquisition, disposal, voting or other disposition of the Shares registered in their name or otherwise held by them. There are no side agreements or arrangements between us and the Cornerstone Investors or any benefit, direct or indirect, conferred on the Cornerstone Investors by virtue of or in relation to the Cornerstone Placing, other than a guaranteed allocation of the relevant Offer Shares at the Offer Price. As confirmed by each Cornerstone Investor, its subscription under the Cornerstone Placing would be financed by its own internal financial resources.

The Cornerstone Placing forms part of the International Offering, and the Cornerstone Investors will not acquire any Offer Shares under the Global Offering other than pursuant to the Cornerstone Investment Agreements. The Offer Shares to be subscribed by the Cornerstone Investors will rank pari passu in all respects with the fully paid Shares in issue following the completion of the Global Offering and for the purpose of Rule 8.08 of the Listing Rules. Immediately following the completion of the Global Offering, none of the Cornerstone Investors will become a substantial Shareholder (as defined in the Listing Rules) of the Company nor have any Board representation in the Company. Other than a guaranteed allocation of the relevant Offer Shares at the Offer Price, the Cornerstone Investors do not have any preferential rights in the Cornerstone Investment Agreements compared with other public Shareholders. There are no side agreements or arrangements between us and the Cornerstone Investors concerning the relevant cornerstone investment.

Each of the Cornerstone Investors has agreed that it will not, whether directly or indirectly, at any time during the period of six (6) months from the Listing Date, dispose of any of the Offer Shares they have purchased pursuant to the relevant Cornerstone Investment Agreement, save for certain limited circumstances, such as transfers to any of its wholly-owned subsidiaries, an affiliated fund under common management or control with the relevant Cornerstone Investor or a fund or an account which investments are managed by the investment manager of the relevant Cornerstone Investor or an investment manager under common management or control with the relevant Cornerstone Investor's investment manager or affiliate, who will be bound by the same obligations of such Cornerstone Investor, including the Lock-up Period restriction.

Please refer to the section headed “Cornerstone Placing” in the Prospectus for further details relating to the Cornerstone Investors.

Places with the Consent under Paragraph 5(1) of the Placing Guidelines

Certain Offer Shares were placed to three places who are connected clients of certain lead brokers or distributors within the meaning of the Placing Guidelines. The Shares to be placed to CSII and CICC FT (as defined below) will be held by them on non-discretionary basis, while the shares to be placed to Bosera International will be held by it on a discretionary basis. The Shares to be allocated to the below places will be held by them on behalf of independent third parties who are not connected to the Company for the purpose of the Listing Rules. The Company has applied to the Exchange for, and the Stock Exchange has granted, its consent under paragraph 5(1) of the Placing Guidelines to permit the Company to allocate such Offer Shares as set out below.

Placee	Connected Syndicate Members or Distributors	Relationship with the Connected Syndicate Members or Distributors	Number of Offer Shares placed	Approximate % of the Offer Shares initially available under the Global Offering ⁽¹⁾	Approximate % of the total issued share capital immediately following the completion of the Global Offering ⁽¹⁾
China Securities (International) Investment Company Limited (“CSII”) ⁽²⁾⁽⁵⁾	China Securities (International) Brokerage Company Limited (“CSIB”)	Both CSII and CSIB are wholly-owned subsidiaries of China Securities (International) Finance Holdings Company Limited, which is in turn wholly-owned by CSC Financial Co. Ltd. CSII and CSIB are members of the same group of companies.	15,893,000	11.50%	2.59%
Bosera Asset Management (International) Co., Limited (“Bosera International”) ⁽³⁾	China Merchants Securities (HK) Co., Limited (“CMSHK”)	CMSHK is a wholly-owned subsidiary of China Merchants Securities Co., Ltd., which owns approximately 49% of Bosera Asset Management Co Limited (“Bosera”), and Bosera International is a wholly-owned subsidiary of Bosera. Therefore, Bosera International is a member of the same group of companies as CMSHK.	1,740,000	1.26%	0.28%
CICC Financial Trading Limited (“CICC FT”) ⁽⁴⁾⁽⁵⁾	China International Capital Corporation Hong Kong Securities Limited (“CICC”)	CICC FT is a wholly owned subsidiary of China International Capital Corporation Limited, which wholly owns CICC. CICC FT and CICC are members of the same group of companies.	4,973,000	3.60%	0.81%
Total			22,606,000	16.36%	3.68%

Notes:

- (1) Based on the assumption that the Over-allotment Option is not exercised.
- (2) CSII shall hold the Offer Shares for and on behalf of SUNON Jixiang Private Equity Investment Fund No. 1* (謝諾辰陽吉祥 1 號私募證券投資基金) (“**Ultimate Client**”) on a non-discretionary basis only to hedge a series of cross border delta-one OTC swap transactions to be entered into between CSII, CSC Financial Co. Ltd (“**CSCF**”) and the Ultimate Client (the “**Client TRS**”), to facilitate the participation of the Ultimate Client in the Global Offering. CSII will also enter into back-to-back transactions with CSCF (the “**Back-to-back TRS**”, together with the Client TRS, the “**TRS**”). The TRS will be fully funded by the Ultimate Client. With the arrangement of the TRS, CSII will hold the legal title and the voting right of the relevant Offer Shares by itself on a non-discretionary basis, and pass through all economic returns of the relevant Offer Shares to the Ultimate Client and all economic loss shall be borne by the Ultimate Client through the TRS in accordance with the terms and conditions of the TRS documents. CSII will not take part in any economic return or bear any economic loss in relation to the price of the Offer Shares. The Ultimate Client is effectively the actual beneficiary subscribing for the Offer Shares, and CSII merely acts as a passive conduit for the Ultimate Client to facilitate its participation in the Global Offering. As the Ultimate Client is a PRC domestic onshore private equity investment fund, and it cannot directly participate in the Global Offering, to facilitate the Ultimate Client’s participation in the Global Offering, CSII will hold the Offer Shares while the economic exposures of the Offer Shares will be passed to the Ultimate Client via TRS. The TRS is linked to the relevant Offer Shares and the Ultimate Client may request CSII to redeem the relevant Offer Shares at their own discretions, upon which CSII shall dispose of the relevant Offer Shares and settle TRS in cash in accordance with the terms and conditions of the TRS documents. Although CSII will hold the legal title of the relevant Offer Shares, it will not exercise the voting right of the relevant Offer Shares during the tenure of the TRS documents in accordance with their policy.
- (3) Bosera International, acting as an investment manager, shall hold the Offer Shares for and on behalf of several funds on a discretionary basis.
- (4) CICC FT shall hold the Offer Shares on a non-discretionary basis for the purpose of only hedging the economic exposure under a series of cross border delta-one OTC swap transactions to be entered between CICC FT and China International Capital Corporation Limited and SUNON Jixiang Private Equity Investment Fund No.1* (謝諾辰陽吉祥 1 號私募證券投資基金) (“**Ultimate Client**”) (the “**OTC Swaps**”). CICC FT will pass through the economic exposure of the Offer Shares to the Ultimate Client subject to the terms and conditions of the OTC Swaps documents: (i) during the tenure of the OTC Swaps, all economic returns of the Offer Shares will be passed to the Ultimate Client and all economic loss shall be borne by the Ultimate Client through the OTC Swaps, and CICC FT will not take part in any economic return or bear any economic loss in relation to the price of the Offer Shares; (ii) as the Ultimate Client is a PRC domestic onshore private equity investment fund, and it cannot directly participate in the Global Offering, to facilitate the Ultimate Client’s participation in the Global Offering, CICC FT will hold the Offer Shares while the economic exposures of the Offer Shares will be passed to the Ultimate Client via OTC Swaps; (iii) the OTC Swaps are linked to the Offer Shares and the Ultimate Client may request CICC FT to redeem it at their own discretions, upon which CICC FT shall dispose of the Offer Shares and settle OTC Swaps in cash in accordance with the terms and conditions of the OTC Swap documents; and (iv) despite that CICC FT will hold the title of the Offer Shares by itself, it will not exercise the voting right of the relevant Shares during the terms of the OTC Swaps as per its internal policy.
- (5) The Ultimate Client mentioned under footnote 2 and footnote 4 above refers to the same entity, i.e. SUNON Jixiang Private Equity Investment Fund No. 1* (謝諾辰陽吉祥1號私募證券投資基金).
- (*) The English transliteration is provided for reference only, and the Chinese name shall prevail.

None of the Joint Sponsors, the Joint Representatives, the Joint Global Coordinators, the Joint Bookrunners, the Joint Lead Managers, the Underwriters and their respective affiliated companies and connected clients of the lead broker or of any distributors (as defined in the Placing Guidelines) has taken up any Offer Shares for its own benefit under the Global Offering. The Offer Shares placed to the above placees are in compliance with all the conditions under the consent granted by the Stock Exchange. There is no restriction on disposal of the Offer Shares allocated to each of such connected clients.

Over-allotment Option

In connection with the Global Offering, the Company has granted the Over-allotment Option to the International Underwriters, exercisable by the Joint Representatives on behalf of the International Underwriters, at any time from the date of the Listing Date to Friday, June 10, 2022, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering, to require the Company to allot and issue up to an aggregate of 20,728,000 additional Offer Shares, representing approximately 15% of the initial number of Offer Shares to be offered in the Global Offering, at the Offer Price to cover the over-allocations in the International Offering, if any. There has been an over-allocation of 20,728,000 Offer Shares in the International Offering and such over-allocation will be settled by using Shares to be borrowed under the Stock Borrowing Agreement between YK Development and the Stabilizing Manager. Such borrowed Shares will be covered by exercising the Over-allotment Option in full or in part, or by making purchases in the secondary market at prices that do not exceed the Offer Price, or a combination of these means. In the event the Over-allotment Option is exercised, an announcement will be made on the Company's website at www.yunkanghealth.com and on the Stock Exchange's website at www.hkexnews.hk, respectively. As of the date of this announcement, the Over-allotment Option has not been exercised.

LOCK-UP UNDERTAKINGS

Each of the Company, Controlling Shareholders, Warranting Shareholders and Cornerstone Investors has given certain undertakings in relation to the issue or disposal of Shares (the “**Lock-up Undertakings**”). The major terms of the Lock-up Undertakings are set out as follows:

Name	Number of shares held in the Company subject to the Lock-up Undertakings upon Listing	Percentage of shareholding in the Company subject to the Lock-up Undertakings upon Listing ⁽¹⁾	Last day subject to the Lock-up Undertakings
<i>The Company (subject to lock-up obligations pursuant to the Listing Rules and the Hong Kong Underwriting Agreement)</i>	N/A	N/A	November 17, 2022 ⁽²⁾
<i>The Controlling Shareholders (subject to lock-up obligations pursuant to the Listing Rules)</i>			
Zhang Yong (張勇), YK Development, Huizekx Limited, Mouduans Limited, Tongfuzc Limited, WJJR Investment Limited, Jin Jun Ying Limited, Source Capital RW Limited	250,108,000	40.79%	November 17, 2022 ⁽³⁾
– First six-month period from the Listing Date			May 17, 2023 ⁽³⁾
– Second six-month period from the Listing Date			
Da An Gene, Daan International, Guangzhou Daan Gene Technology Co., Ltd. (廣州市達安基因科技有限公司)	209,783,000	34.21%	

Name	Number of shares held in the Company subject to the Lock-up Undertakings upon Listing	Percentage of shareholding in the Company subject to the Lock-up Undertakings upon Listing ⁽¹⁾	Last day subject to the Lock-up Undertakings
– First six-month period from the Listing Date			November 17, 2022 ⁽³⁾
– Second six-month period from the Listing Date			May 17, 2023 ⁽³⁾
<i>The Warranting Shareholders (subject to lock-up obligations pursuant to the Listing Rules and the Hong Kong Underwriting Agreement)</i>			
Zhang Yong (張勇), YK Development, Huizekx Limited, Mouduans Limited	250,108,000	40.79%	
– First six-month period from the Listing Date			November 17, 2022 ⁽³⁾
– Second six-month period from the Listing Date			May 17, 2023 ⁽³⁾
Da An Gene, Daan International, Guangzhou Daan Gene Technology Co., Ltd. (廣州市達安基因科技有限公司)	209,783,000	34.21%	
– First six-month period from the Listing Date			November 17, 2022 ⁽³⁾
– Second six-month period from the Listing Date			May 17, 2023 ⁽³⁾
<i>Cornerstone Investors (subject to lock-up obligations pursuant to the Cornerstone Investment Agreements)</i>			
Harvest International Premium Value (Secondary Market) Fund SPC acting on behalf of Harvest High Yield SP	29,835,500	4.87%	November 17, 2022 ⁽³⁾
YHLO (Hong Kong) Limited	7,956,000	1.30%	November 17, 2022 ⁽³⁾

Notes:

- (1) Based on the assumption that the Over-allotment Option is not exercised.
- (2) The Company may not allot or issue Shares prior to the indicated date except otherwise permitted by the Listing Rules and the Stock Exchange.
- (3) Relevant Shares can be dealt with freely on the day after the date indicated (subject to any restriction disclosed herein and in the Prospectus).

BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING

Subject to the satisfaction of the conditions set out in the paragraph headed “Structure of the Global Offering – Conditions of the Global Offering” in the Prospectus, 4,025 valid applications made by the public through the **HK eIPO White Form** service and the **CCASS EIPO** service will be conditionally allocated on the basis set out below:

No. of Shares applied for	No. of valid applications	Basis of allotment/ballot	Approximate percentage allotted of the total No. of Shares applied for
POOL A			
500	2,532	500 shares	100.00%
1,000	584	1,000 shares	100.00%
1,500	203	1,500 shares	100.00%
2,000	160	2,000 shares	100.00%
2,500	114	2,500 shares	100.00%
3,000	50	3,000 shares	100.00%
3,500	28	3,500 shares	100.00%
4,000	29	4,000 shares	100.00%
4,500	11	4,500 shares	100.00%
5,000	69	5,000 shares	100.00%
6,000	35	5,500 shares	91.67%
7,000	17	6,000 shares	85.71%
8,000	13	6,500 shares	81.25%
9,000	12	7,000 shares	77.78%
10,000	52	7,500 shares	75.00%
15,000	26	9,500 shares	63.33%
20,000	16	11,500 shares	57.50%
25,000	12	13,500 shares	54.00%
30,000	12	15,500 shares	51.67%
35,000	1	17,500 shares	50.00%
40,000	4	19,500 shares	48.75%
45,000	2	21,500 shares	47.78%
50,000	8	23,500 shares	47.00%
60,000	2	28,000 shares	46.67%
70,000	2	32,500 shares	46.43%
100,000	12	46,000 shares	46.00%
200,000	2	88,000 shares	44.00%
300,000	6	131,000 shares	43.67%
400,000	2	174,500 shares	43.63%
500,000	2	218,000 shares	43.60%
600,000	2	261,000 shares plus 1 out of 2 applicants to receive an additional 500 shares	43.54%
Total	<u>4,020</u>	Total number of Pool A successful applicants: 4,020	

No. of Shares applied for	No. of valid applications	Basis of allotment/ballot	Approximate percentage allotted of the total No. of Shares applied for
POOL B			
700,000	2	700,000 shares	100.00%
1,000,000	2	1,000,000 shares	100.00%
2,000,000	1	2,000,000 shares	100.00%
Total	<u>5</u>	Total number of Pool B successful applicants: 5	

The final number of Offer Shares under the Hong Kong Public Offering is 13,819,000 Offer Shares, representing approximately 10% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option).

RESULTS OF ALLOCATIONS

The results of allocations of the Hong Kong Offer Shares under the Hong Kong Public Offering successfully applied for through the **HK eIPO White Form** services or through the **CCASS EIPO** service, including the Hong Kong identity card, passport, Hong Kong business registration or certificate of incorporation numbers of successful applicants (where applicable) and the number of Hong Kong Offer Shares successfully applied for, will be made available at the times and date and in the manner specified below:

- in the announcement to be posted on the Company’s website at www.yunkanghealth.com and the Stock Exchange’s website at www.hkexnews.hk by no later than 8:00 a.m. on Tuesday, May 17, 2022. Please note that the list of identification document numbers in this announcement may not be a complete list of successful applicants since only successful applicants whose identification document numbers are provided to HKSCC by CCASS Participants are disclosed. Applicants with beneficial names only but not identification document numbers are not disclosed due to personal privacy issue as elaborated below. Applicants who applied for the Offer Shares through their brokers can consult their brokers to enquire about their application result;
- from the “IPO Results” function in the **IPO App** or the designated results of allocations website at www.tricor.com.hk/ipo/result or www.hkeipo.hk/IPOResult with a “search by ID” function on a 24-hour basis from 8:00 a.m. on Tuesday, May 17, 2022 to 12:00 midnight on Monday, May 23, 2022; and
- from the results allocation telephone enquiry line by calling +852 3691 8488 between 9:00 a.m. and 6:00 p.m. on Tuesday, May 17, 2022 to Friday, May 20, 2022.

This announcement contains a list of identification document numbers. Identification document numbers shown in the section headed “Results of Applications Made by **HK eIPO White Form**” refer to Hong Kong identity card numbers/passport numbers/Hong Kong business registration numbers/certificate of incorporation numbers/beneficial owner identification codes (if such applications are made by nominees as agent for the benefit of another person) whereas those displayed in the section headed “Results of Applications Made by Giving **Electronic Application Instructions** to HKSCC via CCASS” are provided by CCASS Participants via CCASS. Therefore, the identification document numbers shown in the two sections are different in nature.

Since applications are subject to personal information collection statements, beneficial owner identification codes displayed in the sections headed “Results of Applications Made by **HK eIPO White Form**” and “Results of Applications Made by Giving **Electronic Application Instructions** to HKSCC via CCASS” are redacted and not all details of applications are disclosed in this announcement.

The level of indications of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of application of the Hong Kong Offer Shares will be published on Tuesday, May 17, 2022 on the website of the Stock Exchange at www.hkexnews.hk and our Company’s website at www.yunkanghealth.com.

SHAREHOLDING CONCENTRATION ANALYSIS

A summary of allotment results under the International Offering is set out below:

- subscription and number of Shares held by the top 1, 5, 10, 15, 20 and 25 of the placees out of the final International Offer Shares, total Offer Shares and total issued share capital of the Company upon Listing:

Placee	Subscription	Aggregate Number of Shares held upon Listing	Subscription as % of International Offering (assuming no exercise of the Over-allotment Option)	Subscription as % of International Offering (assuming the Over-allotment Option is exercised in full)	Subscription as % of total Offer Shares (assuming no exercise of the Over-allotment Option)	Subscription as % of Offer Shares (assuming the Over-allotment Option is exercised in full)	% of total issued share capital upon Listing (assuming no exercise of the Over-allotment Option)	% of total issued share capital upon Listing (assuming the Over-allotment Option is exercised in full)
Top 1	29,835,500	29,835,500	23.99%	20.56%	21.59%	18.77%	4.87%	4.71%
Top 5	85,956,500	85,956,500	69.11%	59.24%	62.20%	54.09%	14.02%	13.56%
Top 10	124,593,500	124,593,500	100.18%	85.87%	90.16%	78.40%	20.32%	19.65%
Top 15	137,067,000	137,067,000	110.21%	94.47%	99.19%	86.25%	22.35%	21.62%
Top 20	142,618,500	142,618,500	114.67%	98.29%	103.21%	89.74%	23.26%	22.50%
Top 25	144,110,500	144,110,500	115.87%	99.32%	104.29%	90.68%	23.50%	22.73%

- number of Shares held by the top 1, 5, 10, 15, 20, 25 of all the Shareholders out of the final International Offer Shares, total Offer Shares and total issued share capital of the Company upon Listing:

Shareholders	Subscription	Aggregate Number of Shares held upon Listing	Subscription as % of International Offering (assuming no exercise of the Over-allotment Option)	Subscription as % of International Offering (assuming the Over-allotment Option is exercised in full)	Subscription as % of total Offer Shares (assuming no exercise of the Over-allotment Option)	Subscription as % of Offer Shares (assuming the Over-allotment Option is exercised in full)	% of total issued share capital upon Listing (assuming no exercise of the Over-allotment Option)	% of total issued share capital upon Listing (assuming the Over-allotment Option is exercised in full)
Top 1	-	250,108,000	0.00%	0.00%	0.00%	0.00%	40.79%	39.45%
Top 5	65,619,000	525,510,000	52.76%	45.22%	47.49%	41.29%	85.70%	82.90%
Top 10	113,703,500	573,594,500	91.42%	78.36%	82.28%	71.55%	93.54%	90.48%
Top 15	124,593,500	599,050,000	100.18%	85.87%	90.16%	78.40%	97.69%	94.50%
Top 20	137,078,000	611,534,500	110.22%	94.47%	99.20%	86.26%	99.73%	96.47%
Top 25	144,337,000	618,793,500	116.06%	99.48%	104.45%	90.83%	100.91%	97.61%

In view of the high concentration of shareholding in a small number of Shareholders, Shareholders and prospective investors should be aware that the price of the Shares could move substantially even with a small number of Shares traded, and should exercise extreme caution when dealing in Shares.